Indivior surges ahead with 14% revenue growth and major merger

• Indivior reported Q2 revenue of $343 million, supported by record SUBLOCADE revenue of $253 million.
• Indivior shares were down 0.52% at $40.01 during Monday trading.
• Indivior raised its 2026 guidance and agreed to an all-stock merger with Supernus.

Indivior Pharmaceuticals (NASDAQ:INDV) reported Q2 revenue of $343 million, up 14%, and announced an all-stock Supernus merger.

SUBLOCADE revenue increased 21% to a quarterly record of $253 million, including $238 million from the United States.

U.S. SUBLOCADE dispense units rose 18%, while the treatment recorded 32,816 new patient starts during the quarter.

Looking ahead, Indivior raised 2026 revenue guidance to $1.295–$1.365 billion and adjusted EBITDA guidance to $700–$740 million.

Following the announcement, Indivior's share price was down 0.52% at $40.01.

Meanwhile, Indivior generated $122 million in GAAP net income and record adjusted EBITDA of $186 million, up 111%.

The company also repurchased $175 million of shares and said its Supernus merger is expected to close during Q4 2026.